Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$20.63 - $30.17 $400,036 - $585,026
19,391 New
19,391 $400,000
Q4 2022

Feb 14, 2023

SELL
$26.28 - $33.92 $41,469 - $53,525
-1,578 Reduced 10.8%
13,029 $362,000
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $17,607 - $26,123
-678 Reduced 4.44%
14,607 $448,000
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $319,150 - $537,879
15,285 New
15,285 $450,000
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $226,451 - $292,541
-5,317 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$48.48 - $78.23 $204,682 - $330,287
-4,222 Reduced 44.26%
5,317 $268,000
Q2 2021

Aug 16, 2021

SELL
$50.3 - $78.44 $789,810 - $1.23 Million
-15,702 Reduced 62.21%
9,539 $748,000
Q1 2021

May 17, 2021

BUY
$53.8 - $81.53 $949,354 - $1.44 Million
17,646 Added 232.34%
25,241 $1.44 Million
Q4 2020

Feb 16, 2021

BUY
$36.89 - $93.56 $280,179 - $710,588
7,595 New
7,595 $636,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.12B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.